Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tianyin Pharmaceutical is preparing to project its newly built QLF pre-extraction facility for inspection by China’s State Food and Drug Administration (SFDA), which is expected to start in mid to end August 2013.
Subscribe to our email newsletter
The company, which specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), has installed a series of equipments at the centre, since its completion in April.
Besides these, employees at QLF carried various required procedures in May and June, which are vital to obtain GMP certification from SFDA.
Leveraging a multi-step process, including precipitation, filtration, centrifugation, concentration and purification, the pre-extraction facility will process, extract and purify TCM pharmaceutical ingredients from natural herbs and raw materials.
After this, the TCM pharma ingredients will be further formulated and integrated for the production of modernized products at the formulation facility.
Headquartered at Chengdu, China, TPI currently produces a complete suite of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list of China.